Interviews with leading Life Sciences companies: tella inc.

Leveraging its proprietary technology of culturing highly purified dendritic cells (DCs), tella is developing, as its first immunotherapeutic product, a DC-based vaccine in combination with WT1 (Wilms’ tumor gene 1) antigen for inoperable pancreatic cancer. Venture Valuation (VV) interviewed Dr. Yuichiro Yazaki, President and CEO. Read the interview

Read more

The Launch of the BioAlberta Life Sciences Database

Zurich, Edmonton January 2018 BioAlberta, a Canadian life sciences industry organization, has recently become a new business partner of Venture Valuation/Biotechgate. BioAlberta gathers a flourishing biotech community comprised of around 170 life sciences companies, government organizations, support service providers, and research & academic institutions, situated across the province. As per the partnership agreement, Venture Valuation … Continue reading The Launch of the BioAlberta Life Sciences Database

Read more

Life Sciences BC – New Canadian Partner for Venture Valuation/Biotechgate

Zurich/Vancouver January 2018 Biotechgate/Venture Valuation announce entering a partnership with Life Sciences British Columbia, a Canadian non-profit organization. The goal of the partnership is to develop and run a database comprised of the life science companies situated in the province of British Columbia. The database will be integrated into the Life Sciences BC website (lifesciencesbc.ca) … Continue reading Life Sciences BC – New Canadian Partner for Venture Valuation/Biotechgate

Read more

Valuation Workshop at RESI Conference – Boston, September 2017

During the last RESI (Redefining Early Stage Investments) Conference – the event series organized by Life Science Nation, a Venture Valuation long-time partner – Dr. Patrik Fried delivered a session on life science deal and product valuations. The notes from the workshop are available to download here

Read more